BDSX Biodesix

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients

LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate, learn, and advocate for lung health.

First Event: October 9th APAPP Know Your Nodules Event at Biodesix Head Office in Louisville, CO

The Association of Pulmonary Advanced Practice Providers (APAPP) Leadership and expert Faculty will run a half-day event: Know Your Nodules: Personalize. Prioritize. Prevent. APAPP Leadership will be hosting a clinician-centered lung disease and lung cancer screening / detection learning event at the Biodesix Corporate Headquarters in Louisville, Colorado. The event will also be live streamed. Faculty includes Corinne Young (President & Founder, APAPP), Stephen Deppen, PhD (Associate Professor of Thoracic Surgery and Epidemiology, Vanderbilt Medical Center), Rebecca Priebe (Acute Care Nurse Practitioner, Henry Ford Health), and Tammy Welch (Physician Assistant, Frederick Regional Health System).

Second Event: October 9th – 11th Go2 for Lung Cancer Centers of Excellence Summit in Denver, CO

The Go2 Association is hosting their annual Lung Cancer Centers of Excellence Summit in downtown Denver. This highly specialized educational event includes a full-day Lung Cancer Nurse Navigator module. Biodesix is a proud supporter of Go2 as they are driving to standardize best practices in lung nodule management at a national level. .

Third Event: October 12th American Lung Association in Colorado “Run the Rocks” at Red Rocks Amphitheater in Morrison, CO

The American Lung Association in Colorado holds their annual Run the Rocks fundraiser and community awareness event at the world-renowned Red Rocks Amphitheater. The purpose of this event is to raise funds for education, research, and advocacy to save lives by improving lung health and preventing lung disease. .

“It is a privilege and honor to collaborate with these three partners here in our home state of Colorado. They each uniquely assist in our journey to achieve the Biodesix mission to conquer lung diseases through personalized diagnostics,” said Scott Hutton, CEO at Biodesix. "I’d also like to note that these October events are well-timed as forerunners for November, which is Lung Cancer Awareness Month -- an important time of year for Biodesix advocacy and awareness efforts.”

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:

Media:

Natalie St. Denis, Director Corporate Communications, Biodesix



(720) 925-9285

Investors:

Chris Brinzey, Partner, ICR



(339) 970-2843



EN
06/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

 PRESS RELEASE

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

 PRESS RELEASE

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results...

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Anal...

 PRESS RELEASE

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Resul...

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining t...

 PRESS RELEASE

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch